Skip to main content

Advertisement

SpringerLink
Log in

Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation

  • Original Article—Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Indigo Naturalis (IN) is used as a traditional herbal medicine for ulcerative colitis (UC). However, the mechanisms of action of IN have not been clarified. We aimed to evaluate the efficacy of IN for ameliorating colonic inflammation. We further investigated the mechanisms of action of IN.

Methods

Colitis severity was assessed in dextran sodium sulfate-induced colitis and trinitrobenzene sulfonic acid-induced colitis models with or without the oral administration of IN or indigo, which is a known major component of IN. Colonic lamina propria (LP) mononuclear cells isolated from IN-treated mice were analyzed with quantitative reverse transcription polymerase chain reaction (qRT-PCR) and flow cytometry. LP and splenic mononuclear cells cultured in vitro with IN or indigo were also analyzed. The role of the candidate receptor for indigo, the aryl hydrocarbon receptor (AhR), was analyzed using Ahr-deficient mice.

Results

Colitis severity was significantly ameliorated in the IN and indigo treatment groups compared with the control group. The mRNA expression levels of interleukin (Il)-10 and Il-22 in the LP lymphocytes were increased by IN treatment. The treatment of splenocytes with IN or indigo increased the expression of anti-inflammatory cytokines and resulted in the expansion of IL-10-producing CD4+ T cells and IL-22-producing CD3−RORγt+ cells, but not CD4+Foxp3+ regulatory T cells. The amelioration of colitis by IN or indigo was abrogated in Ahr-deficient mice, in association with diminished regulatory cytokine production.

Conclusions

IN and indigo ameliorated murine colitis through AhR signaling activation, suggesting that AhR could be a promising therapeutic target for UC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

AhR:

Aryl hydrocarbon receptor

CD:

Crohn’s disease

CECs:

Colonic epithelial cells

DMSO:

Dimethyl sulfoxide

DSS:

Dextran sodium sulfate

Foxp3:

Forkhead box p3

IBD:

Inflammatory bowel disease

ILC:

Innate lymphoid cells

IN:

Indigo Naturalis

LP:

Lamina propria

MLN:

Mesenteric lymph node

RORγ:

RAR-related orphan receptor gamma

TCDD:

2,3,7,8-Tetrachlorodibenzo-p-dioxin

TNBS:

Trinitrobenzene sulfonic acid

Tr1 cells:

Type 1 regulatory T cells

UC:

Ulcerative colitis

References

  1. Ochsenkühn T, D’Haens G. Current misunderstandings in the management of ulcerative colitis. Gut. 2011;60:1294–9.

    Article  PubMed  Google Scholar 

  2. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909–15.

    Article  CAS  PubMed  Google Scholar 

  3. Ng SC, Lam YT, Tsoi KK, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:854–63.

    Article  CAS  PubMed  Google Scholar 

  4. Triantafyllidi A, Xanthos T, Papalois A, et al. Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol. 2015;28:210–20.

    PubMed  PubMed Central  Google Scholar 

  5. Plitzko I, Mohn T, Sedlacek N, et al. Composition of Indigo naturalis. Planta Med. 2009;75:860–3.

    Article  CAS  PubMed  Google Scholar 

  6. Deng S, May BH, Zhang AL, et al. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:769–82.

    Article  CAS  PubMed  Google Scholar 

  7. Suzuki H, Kaneko T, Mizokami Y, et al. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World J Gastroenterol. 2013;19:2718–22.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fukunaga K, Ohda Y, Hida N, et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol. 2012;27:1808–15.

    Article  PubMed  Google Scholar 

  9. Zhang F, Li Y, Xu F, et al. Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. J Altern Complement Med. 2013;19:838–42.

    Article  PubMed  Google Scholar 

  10. Sugimoto S, Naganuma M, Kiyohara H, et al. Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study. Digestion. 2016;93:193–201.

    Article  CAS  PubMed  Google Scholar 

  11. Sugimoto S, Naganuma M, Kanai T. Indole compounds may be promising medicines for ulcerative colitis. J Gastroenterol. 2016;51:853–61.

    Article  CAS  PubMed  Google Scholar 

  12. Stockinger B, Di Meglio P, Gialitakis M, et al. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–32.

    Article  CAS  PubMed  Google Scholar 

  13. Sugihara K, Okayama T, Kitamura S, et al. Comparative study of aryl hydrocarbon receptor ligand activities of six chemicals in vitro and in vivo. Arch Toxicol. 2008;82:5–11.

    Article  CAS  PubMed  Google Scholar 

  14. Adachi J, Mori Y, Matsui S, et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem. 2001;276:31475–8.

    Article  CAS  PubMed  Google Scholar 

  15. Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011;141:237–48, 248.e1.

  16. Nguyen NT, Nakahama T, Le DH, et al. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol. 2014;5:551.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Shiraishi E, Iijima H, Shinzaki S, et al. Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis. J Gastroenterol. 2016;51:346–56.

    Article  CAS  PubMed  Google Scholar 

  18. Li Y, Innocentin S, Withers DR, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011;147:629–40.

    Article  CAS  PubMed  Google Scholar 

  19. Shinzaki S, Ishii M, Fujii H, et al. N-acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis. J Gastroenterol. 2016;51:357–69.

  20. Furumatsu K, Nishiumi S, Kawano Y, et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci. 2011;56:2532–44.

    Article  CAS  PubMed  Google Scholar 

  21. Aicher WK, Fujihashi K, Yamamoto M, et al. Effects of the lpr/lpr mutation on T and B cell populations in the lamina propria of the small intestine, a mucosal effector site. Int Immunol. 1992;4:959–68.

    Article  CAS  PubMed  Google Scholar 

  22. Lee J, Park EJ, Yuki Y, et al. Profiles of microRNA networks in intestinal epithelial cells in a mouse model of colitis. Sci Rep. 2015;5:18174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dohi T, Ejima C, Kato R, et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology. 2005;128:411–23.

    Article  CAS  PubMed  Google Scholar 

  24. Iijima H, Neurath MF, Nagaishi T, et al. Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J Exp Med. 2004;199:471–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gandhi R, Kumar D, Burns EJ, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol. 2010;11:846–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013;252:116–32.

    Article  PubMed  Google Scholar 

  27. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145–9.

    Article  CAS  PubMed  Google Scholar 

  28. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309–34.

    Article  CAS  PubMed  Google Scholar 

  29. Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33:747–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chiang YR, Li A, Leu YL, et al. An in vitro study of the antimicrobial effects of indigo naturalis prepared from Strobilanthes formosanus Moore. Molecules. 2013;18:14381–96.

    Article  PubMed  Google Scholar 

  31. Xiao HT, Peng J, Hu DD, et al. Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice. Chin Med. 2015;10:29.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Li Y, Ligr M, McCarron JP, et al. Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion. Clin Cancer Res. 2011;17:4414–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549.

    Article  CAS  PubMed  Google Scholar 

  34. Takamura T, Harama D, Matsuoka S, et al. Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis in mice. Immunol Cell Biol. 2010;88:685–9.

    Article  CAS  PubMed  Google Scholar 

  35. Kociba RJ, Schwetz BA. Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Drug Metab Rev. 1982;13:387–406.

  36. Pot C. Aryl hydrocarbon receptor controls regulatory CD4+ T cell function. Swiss Med Wkly. 2012;142:w13592.

    PubMed  Google Scholar 

  37. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28–50.

    Article  CAS  PubMed  Google Scholar 

  38. Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42.

    Article  CAS  PubMed  Google Scholar 

  39. Apetoh L, Quintana FJ, Pot C, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2010;11:854–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Mascanfroni ID, Takenaka MC, Yeste A, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. Nat Med. 2015;21:638–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Qiu J, Heller JJ, Guo X, et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92–104.

    Article  CAS  PubMed  Google Scholar 

  42. Wagage S, Harms Pritchard G, Dawson L, et al. The group 3 innate lymphoid cell defect in aryl hydrocarbon receptor deficient mice is associated with T cell hyperactivation during intestinal infection. PLoS One. 2015;10:e0128335.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Nikoopour E, Bellemore SM, Singh B. IL-22, cell regeneration and autoimmunity. Cytokine. 2015;74:35–42.

    Article  CAS  PubMed  Google Scholar 

  44. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Ji T, Xu C, Sun L, et al. Aryl hydrocarbon receptor activation down-regulates IL-7 and reduces inflammation in a mouse model of DSS-induced colitis. Dig Dis Sci. 2015;60:1958–66.

    Article  CAS  PubMed  Google Scholar 

  46. Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50:495–507.

    Article  CAS  PubMed  Google Scholar 

  47. Zhao Y, Ma T, Chen W, et al. MicroRNA-124 promotes intestinal inflammation by targeting aryl hydrocarbon receptor in Crohn’s disease. J Crohns Colitis. 2016;10:703–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Supported by a Grant-in-Aid from the Japan Society for the Promotion of Science (Grant No. 26460969).

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Shoichiro Kawai, Hideki Iijima, Shinichiro Shinzaki, Satoshi Hiyama, Toshio Yamaguchi, Manabu Araki, Shuko Iwatani, Takahiro Inoue, Yoshito Hayashi, Masahiko Tsujii & Tetsuo Takehara

  2. Department of Inflammatory Bowel Disease, Osaka University Graduate School of Medicine, Suita, Japan

    Satoshi Hiyama

  3. Department of Gastroenterology and Hepatology, Sumitomo Hospital, Osaka, Japan

    Eri Shiraishi & Akira Mukai

  4. Department of Gastroenterology and Hepatology, Higashiosaka City General Hospital, Higashiosaka, Japan

    Masahiko Tsujii

  5. Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

    Daisuke Motooka, Shota Nakamura & Tetsuya Iida

Authors
  1. Shoichiro Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Iijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinichiro Shinzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoshi Hiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshio Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manabu Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shuko Iwatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eri Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akira Mukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takahiro Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshito Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masahiko Tsujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Daisuke Motooka
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shota Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tetsuya Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Tetsuo Takehara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Iijima.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 55 kb)

Supplementary material 2 (DOCX 55 kb)

535_2016_1292_MOESM3_ESM.tif

Fig. S1. Flow cytometric analysis of the LP mononuclear cells of mice treated with IN. Similar populations of CD4-IL-10+cells (A) and CD3+IL-22+cells (B) were observed in IN-treated and control mice. A representative figure for flow cytometric analysis is shown on the left side (A). Shaded area isotype control, solid line IN, dotted line control. The data are expressed as the mean + standard error of 3 mice per group (TIFF 785 kb)

535_2016_1292_MOESM4_ESM.tif

Fig. S2. Cytokine expression profiles of the MLN mononuclear cells of mice treated with IN. Cytokine expression levels in the MLN cells isolated from mice with DSS-induced colitis were not significantly different between the high-dose IN treatment (IN) and control groups. The expression of Il-22 mRNA was undetectable in both groups. The measurements are expressed as the mean + standard error of 5 mice. *p < 0.05 (TIFF 985 kb)

535_2016_1292_MOESM5_ESM.tif

Fig. S3. Cytokine expression profile of the splenic mononuclear cells in mice treated with IN. Cytokine expression levels in the splenocytes isolated from mice with DSS-induced colitis were not significantly different between the high-dose IN treatment (IN) and control groups. The expression of Il-22 was undetectable in both groups. The measurements are expressed as the mean + standard error of 5 mice. *p < 0.05 (TIFF 990 kb)

535_2016_1292_MOESM6_ESM.tif

Fig. S4. Cytokine expression profile in LP mononuclear cells in Ahr-deficient mice treated with or without IN. There were no significant differences between the IN and control groups. The data are expressed as the mean + standard error of 4 mice per group (TIFF 838 kb)

535_2016_1292_MOESM7_ESM.tif

Fig. S5. AHR expression was elevated in the inflamed mucosa of UC patients. The expression levels of AHR mRNA in uninflamed mucosa (Mayo endoscopic score of 0) and inflamed mucosa (Mayo endoscopic score: 1–3) were compared in 10 UC patients. *p < 0.05 (TIFF 712 kb)

535_2016_1292_MOESM8_ESM.tif

Fig. S6. Expressions of STAT3 and phosphorylated (p)-STAT3 in CECs of mice treated with IN or vehicle control. Mice had DSS-induced colitis that was treated with IN or vehicle control. CECs were isolated from the colon by gentle stirring in the medium followed by Percoll gradient. Western blotting of the cellular lysates was performed by using anti-STAT3, anti-phospho-STAT3, and anti-β-actin antibodies. There was no apparent difference in the expression of p-STAT3 between the IN-treated and control groups. The data are representative of three independent experiments (TIFF 909 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawai, S., Iijima, H., Shinzaki, S. et al. Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation. J Gastroenterol 52, 904–919 (2017). https://doi.org/10.1007/s00535-016-1292-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-016-1292-z

Keywords

Search

Navigation